---
tags: 
title: "Improving the power of drug toxicity measurements by quantitative nuclei imaging"
authors: "Alesya M. Mikheeva, Mikhail A. Bogomolov, Valentina A. Gasca, Mikhail V. Sementsov, Pavel V. Spirin, Vladimir S. Prassolov, Timofey D. Lebedev"
---

> [!Cite] 1.

Mikheeva, A. M. _et al._ Improving the power of drug toxicity measurements by quantitative nuclei imaging. _Cell Death Discov_ **10**, 181 (2024).

>[!md] QAC

>[!md]
> **FirstAuthor**:: Mikheeva, Alesya M.  
> **Author**:: Bogomolov, Mikhail A.  
> **Author**:: Gasca, Valentina A.  
> **Author**:: Sementsov, Mikhail V.  
> **Author**:: Spirin, Pavel V.  
> **Author**:: Prassolov, Vladimir S.  
> **Author**:: Lebedev, Timofey D.  
~    
> **Title**:: Improving the power of drug toxicity measurements by quantitative nuclei imaging  
> **Year**:: 2024   
> **Citekey**:: mikheevaImprovingPowerDrug2024  
> **itemType**:: journalArticle  
> **Journal**:: *Cell Death Discovery*  
> **Volume**:: 10  
> **Issue**:: 1   
> **Pages**:: 181  
> **DOI**:: 10.1038/s41420-024-01950-3    

> [!LINK] 
>
>  [Mikheeva et al. - 2024 - Improving the power of drug toxicity measurements by quantitative nuclei imaging.pdf](file:///Users/romankoval/Library/Mobile%20Documents/com~apple~CloudDocs/Library%20of%20Alexandria/ZotMove_files/Mikheeva%20et%20al.%20-%202024%20-%20Improving%20the%20power%20of%20drug%20toxicity%20measurements%20by%20quantitative%20nuclei%20imaging.pdf).

> [!Abstract]
>
> Imaging-based anticancer drug screens are becoming more prevalent due to development of automated fluorescent microscopes and imaging stations, as well as rapid advancements in image processing software. Automated cell imaging provides many benefits such as their ability to provide high-content data, modularity, dynamics recording and the fact that imaging is the most direct way to access cell viability and cell proliferation. However, currently most publicly available large-scale anticancer drugs screens, such as GDSC, CTRP and NCI-60, provide cell viability data measured by assays based on colorimetric or luminometric measurements of NADH or ATP levels. Although such datasets provide valuable data, it is unclear how well drug toxicity measurements can be integrated with imaging data. Here we explored the relations between drug toxicity data obtained by XTT assay, two quantitative nuclei imaging methods and trypan blue dye exclusion assay using a set of four cancer cell lines with different morphologies and 30 drugs with different mechanisms of action. We show that imaging-based approaches provide high accuracy and the differences between results obtained by different methods highly depend on drug mechanism of action. Selecting AUC metrics over IC50 or comparing data where significantly drugs reduced cell numbers noticeably improves consistency between methods. Using automated cell segmentation protocols we analyzed mitochondria activity in more than 11 thousand drug-treated cells and showed that XTT assay produces unreliable data for CDK4/6, Aurora A, VEGFR and PARP inhibitors due induced cell size growth and increase in individual mitochondria activity. We also explored several benefits of image-based analysis such as ability to monitor cell number dynamics, dissect changes in total and individual mitochondria activity from cell proliferation, and ability to identify chromatin remodeling drugs. Finally, we provide a web tool that allows comparing results obtained by different methods.
>.
>
### Ideas, thoughts, useful information

> [!quote]+ Highlight ([Page ](zotero://open-pdf/library/items/MPIMDNAR?page=1&annotation=H9XULS3I))
> electing AUC metrics over IC50 or comparing data where significantly drugs reduced cell numbers noticeably improves consistency between methods. Using automated cell segmentation protocols we analyzed mitochondria activity in more than 11 thousand drug-treated cells and showed that XTT assay produces unreliable data for CDK4/6, Aurora A, VEGFR and PARP inhibitors due induced cell size growth and increase in individual mitochondria activity. 

> [!quote]+ Highlight ([Page ](zotero://open-pdf/library/items/MPIMDNAR?page=1&annotation=AL6GVLCF))
> Thus, several largest datasets provide drug toxicity data measured by methods, which rely on NADH activity, ATP or protein levels: Genomics of Drug Sensitivity in Cancer (GDSC) uses resazurin and CellTiter-Glo [3], Cancer Therapeutics Response Portal uses CellTiter-Glo [1], and NCI-60 uses sulforhodamine B assay [7]. These methods rely on indirect measurement of drug toxicity, and sometimes can be unreliable because drugs may influence cellular metabolic activity or protein levels without change in cells quantity [8â€“10]. 

> [!quote]+ Highlight ([Page 2](zotero://open-pdf/library/items/MPIMDNAR?page=2&annotation=2APMRTK8))
> XTT measurements significantly differ from quantitative nuclei imaging 

> [!quote]+ Highlight ([Page 2](zotero://open-pdf/library/items/MPIMDNAR?page=2&annotation=3JPGPL5F))
> Variance in IC50 values is caused by combination of particular drug and method 

> [!quote]+ Highlight ([Page 2](zotero://open-pdf/library/items/MPIMDNAR?page=2&annotation=PD2Z94S7))
> Difference in cell viability measurements depends on druginduced mitochondrial activity 

> [!quote]+ Highlight ([Page 3](zotero://open-pdf/library/items/MPIMDNAR?page=3&annotation=8Z5X4VCY))
> H2B-mRuby imaging reveals different cell death dynamics 


[[HTI and regulated necrosis]]